CT83 and neoplasm: This will further confirm that the tumor vaccine targeting KK-LC-1, when combined with immune checkpoint inhibitors, can more effectively activate the anti-tumor immune system, enhance T cell-mediated tumor killing effects, and improve treatment outcomes.